MXPA05012320A - Tratamientos de trastornos bipolares y sintomas asociados. - Google Patents
Tratamientos de trastornos bipolares y sintomas asociados.Info
- Publication number
- MXPA05012320A MXPA05012320A MXPA05012320A MXPA05012320A MXPA05012320A MX PA05012320 A MXPA05012320 A MX PA05012320A MX PA05012320 A MXPA05012320 A MX PA05012320A MX PA05012320 A MXPA05012320 A MX PA05012320A MX PA05012320 A MXPA05012320 A MX PA05012320A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- bipolar disorder
- bipolar
- mammal
- bipolar disorders
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 8
- 208000020925 Bipolar disease Diseases 0.000 title abstract 5
- 208000024891 symptom Diseases 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
La presente invencion se refiere a un procedimiento para los tratamientos relativos a trastorno bipolar en un mamifero, incluyendo un ser humano, incluyendose entre los tratamientos, el tratamiento de trastorno bipolar de ciclo rapido, tratamiento de sintomas de trastorno bipolar, seleccionado entre el grupo constituido por mania aguda y depresion; tratamiento para efectuar estabilizacion de estado de animo; tratamiento para prevenir la recaida en episodios bipolares, y para el tratamiento de pensamientos y tendencias suicidas asociadas a trastorno bipolar, comprendiendo la administracion a dicho mamifero de una cantidad eficaz de un compuesto de formula I (ver formula I): o una sal de adicion de acido farmaceuticamente aceptable del mismo, en la que Ar, n, X e Y son como se han definido.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47145003P | 2003-05-16 | 2003-05-16 | |
| PCT/IB2004/001601 WO2004100957A1 (en) | 2003-05-16 | 2004-05-12 | Treatment of bipolar disorders and associated symptoms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05012320A true MXPA05012320A (es) | 2006-01-30 |
Family
ID=33452446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05012320A MXPA05012320A (es) | 2003-05-16 | 2004-05-12 | Tratamientos de trastornos bipolares y sintomas asociados. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20050038036A1 (es) |
| EP (1) | EP1626723A1 (es) |
| JP (1) | JP2007516955A (es) |
| KR (1) | KR20060009938A (es) |
| CN (1) | CN1780626A (es) |
| AR (1) | AR046586A1 (es) |
| AU (1) | AU2004237961A1 (es) |
| BR (1) | BRPI0410222A (es) |
| CA (1) | CA2525326A1 (es) |
| MX (1) | MXPA05012320A (es) |
| TW (1) | TW200509929A (es) |
| WO (1) | WO2004100957A1 (es) |
| ZA (1) | ZA200508523B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7504395B2 (en) * | 2001-07-20 | 2009-03-17 | Psychogenics, Inc. | Treatment for attention-deficit hyperactivity disorder |
| MY158766A (en) * | 2005-04-11 | 2016-11-15 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| MY145694A (en) | 2005-04-11 | 2012-03-30 | Xenon Pharmaceuticals Inc | Spiroheterocyclic compounds and their uses as therapeutic agents |
| AR056317A1 (es) * | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| JP2009524637A (ja) * | 2006-01-27 | 2009-07-02 | ファイザー・プロダクツ・インク | アミノフタラジン誘導体化合物 |
| CN100491375C (zh) * | 2006-07-01 | 2009-05-27 | 浙江美诺华药物化学有限公司 | 一种齐拉西酮的制备方法 |
| CL2007002953A1 (es) * | 2006-10-12 | 2008-02-01 | Xenon Pharmaceuticals Inc | Compuestos derivados de espiro-oxindol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, prurito, hiperplasia prostatica benigna, hipercolesterolemia. |
| BRPI0719210A2 (pt) * | 2006-10-12 | 2015-05-05 | Xenon Pharmaceuticals Inc | Uso de compostos espiro-oxindol como agentes terapêuticos |
| US20110237567A9 (en) * | 2006-10-12 | 2011-09-29 | Xenon Pharmaceuticals Inc. | Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents |
| CA2741029A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| US8101647B2 (en) * | 2008-10-17 | 2012-01-24 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| WO2011047173A2 (en) * | 2009-10-14 | 2011-04-21 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
| EP2488531B1 (en) | 2009-10-14 | 2014-03-26 | Xenon Pharmaceuticals Inc. | Synthetic methods for spiro-oxindole compounds |
| EP3266444A1 (en) | 2010-02-26 | 2018-01-10 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
| WO2016127068A1 (en) | 2015-02-05 | 2016-08-11 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4883795A (en) * | 1988-01-22 | 1989-11-28 | Pfizer Inc. | Piperazinyl-heterocyclic compounds |
| US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| IL125951A (en) * | 1997-09-05 | 2003-09-17 | Pfizer Prod Inc | A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal |
| IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
| US6387904B2 (en) * | 1998-05-18 | 2002-05-14 | Pfizer Inc | Method of treating glaucoma and ischemic retinopathy |
| SK17492000A3 (sk) * | 1998-05-29 | 2002-04-04 | Eli Lilly And Company | Liek na liečenie bipolárnych porúch a farmaceutický prostriedok |
-
2004
- 2004-05-12 AU AU2004237961A patent/AU2004237961A1/en not_active Abandoned
- 2004-05-12 CN CNA2004800112618A patent/CN1780626A/zh active Pending
- 2004-05-12 MX MXPA05012320A patent/MXPA05012320A/es unknown
- 2004-05-12 CA CA002525326A patent/CA2525326A1/en not_active Abandoned
- 2004-05-12 EP EP04732360A patent/EP1626723A1/en not_active Withdrawn
- 2004-05-12 KR KR1020057021793A patent/KR20060009938A/ko not_active Application Discontinuation
- 2004-05-12 US US10/843,915 patent/US20050038036A1/en not_active Abandoned
- 2004-05-12 BR BRPI0410222-3A patent/BRPI0410222A/pt not_active IP Right Cessation
- 2004-05-12 WO PCT/IB2004/001601 patent/WO2004100957A1/en active Application Filing
- 2004-05-12 JP JP2006530661A patent/JP2007516955A/ja active Pending
- 2004-05-14 TW TW093113690A patent/TW200509929A/zh unknown
- 2004-05-17 AR ARP040101701A patent/AR046586A1/es not_active Application Discontinuation
-
2005
- 2005-10-02 ZA ZA200508523A patent/ZA200508523B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1780626A (zh) | 2006-05-31 |
| AU2004237961A1 (en) | 2004-11-25 |
| AR046586A1 (es) | 2005-12-14 |
| TW200509929A (en) | 2005-03-16 |
| JP2007516955A (ja) | 2007-06-28 |
| US20050038036A1 (en) | 2005-02-17 |
| WO2004100957A1 (en) | 2004-11-25 |
| BRPI0410222A (pt) | 2006-05-09 |
| EP1626723A1 (en) | 2006-02-22 |
| CA2525326A1 (en) | 2004-11-25 |
| KR20060009938A (ko) | 2006-02-01 |
| ZA200508523B (en) | 2007-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007004485A (es) | Tratamiento de desordenes bipolares y sintomas asociados. | |
| MXPA05012320A (es) | Tratamientos de trastornos bipolares y sintomas asociados. | |
| CY1123084T1 (el) | Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι | |
| WO2005023083A3 (en) | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) | |
| MXPA04000993A (es) | MeTODO PARA TRATAR ENFERMEDADES PULMONARES EN MAMIFEROS MEDIANTE LA ALTERACION DE NIVELES NORMALES IN VIVO DE OXIDO NITRICO. | |
| WO2004069190A3 (en) | Combination therapy for treating protein deficiency disorders | |
| UA85055C2 (ru) | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний | |
| WO2005063745A3 (en) | Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof | |
| TNSN04039A1 (en) | Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar-activators | |
| BRPI0406883A (pt) | Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto | |
| MY141972A (en) | Biaryloxymethylarenecarboxylic acids | |
| WO2004105682A3 (en) | Carbostyril derivatives and mood stabilizers for treating mood disorders | |
| BRPI0507657A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo | |
| WO2007075695A3 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder | |
| MXPA05010293A (es) | 4-amino[1,2,4]triazolo[4,3-a]quinoxalinas sustituidas. | |
| WO2004110380A3 (en) | Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents | |
| WO2006088814A3 (en) | Dosage form and method for sustained release of a substituted pyrazine compound | |
| EP1177791A3 (en) | Use of glycogen phosphorylase inhibitors to inhibit tumor growth | |
| WO2006009874A3 (en) | Methods and compositions for treatment of excess nitric oxide or cyanide toxicity | |
| WO2003092617A3 (en) | Combinations for the treatment of inflammatory skin disorders | |
| NZ510920A (en) | Use of (S)-3-(aminomethyl)-5-methylhexanoic acid (pregabalin) to treat acute and chronic mania in humans | |
| BRPI0416882A (pt) | composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto | |
| WO2005089736A3 (en) | Methods for treating inflammatory and autoimmune diseases | |
| MXPA05009242A (es) | Tratamiento de la diabetes tipo 1 con los inhibidores de la pde5. | |
| WO2007095609A3 (en) | Use of benzo-heteroaryl sulfamide derivatives for the treatment of mania and bipolar disorder |